Please select the option that best describes you:
What are your top takeaways in Hematology from ASCO 2025?
Answer from: Medical Oncologist at Academic Institution
I would say:
CARTITUDE-1 updates – first time we are seeing a plateau in a MM trial, that too in the relapsed/refractory setting with 5+ years follow-up.
JNJ-5322 Trispecific – dual antigen targeting with less frequent dosing; 100% response rate in BCMA/GPRC5D naïve relapsed/ref...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The major takeaways:
One-third of patients treated with Carvykti on CARTITUDE-1 had not progressed at 5 years.
Four drug regimens in the front-line setting lead to high rates of sustained MRD negativity at 1 and 2 years.
Peak ALC post Carvykti may be predictive of delayed neurologic toxicity an...
Answer from: Medical Oncologist at Academic Institution
Daver, abstract 6513
Terpos, abstract 7512
Shadman, abstract 7009
The MD Anderson paper reports early response data that are outstanding, albeit in a very small population. We continue to look for a medication that can improve the poor response rate of HMAs in MDS. If somehow altering macroph...
Answer from: Medical Oncologist at Academic Institution
7005 - WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma. Interesting study of the ROR1 ADC zilovertamab in R/R DLBCL in combination with R-GEMOX. This, with respect to DL 2 and DL3, demonstrated an improvement in...
Answer from: Medical Oncologist at Academic Institution
Here are a few that I thought were most interesting:
7507 (Long-term follow-up of CARTITUDE-1). While I do think it is premature to conclude that cilta-cel is curative for a portion of patients, this longer-term follow-up shows a subset of patients who have not yet relapsed after 5 years, which d...